Immunophenotypical features of 14 biopsies from 11 patients with LyP
| Patient no. . | CD30 . | CD2 . | CD3 . | CD4 . | CD5 . | CD8 . | CD20 . | βF1 . | Perforin . | Granzyme B . | ALK1 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1A | + | + | + | + | nd | − | − | nd | nd | nd | − |
| 1B | + | + | −/+ | + | + | − | − | −/+ | − | E | − |
| 2C | + | + | + | + | + | − | − | + | + | nd | − |
| 2D | + | + | + | + | + | − | − | ni | +/− | ni | − |
| 3E | + | +/− | − | + | − | − | − | − | + | − | − |
| 3F | + | − | − | + | − | − | − | E | + | − | − |
| 4 | + | + | E | E | − | − | − | − | E | + | − |
| 5 | + | + | + | E | + | + | − | −/+ | − | −/+ | − |
| 6 | + | +/− | + | + | ni | − | − | ni | −/+ | + | − |
| 7 | + | ni | + | + | ni | − | − | ni | ni | ni | − |
| 8 | + | + | − | + | + | − | − | − | + | + | − |
| 9 | + | + | −/+ | +/− | − | − | − | − | − | E | − |
| 10 | + | + | + | + | + | − | − | ni | ni | ni | − |
| 11 | + | −/+ | +/− | +/− | + | − | − | ni | + | + | − |
| Patient no. . | CD30 . | CD2 . | CD3 . | CD4 . | CD5 . | CD8 . | CD20 . | βF1 . | Perforin . | Granzyme B . | ALK1 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1A | + | + | + | + | nd | − | − | nd | nd | nd | − |
| 1B | + | + | −/+ | + | + | − | − | −/+ | − | E | − |
| 2C | + | + | + | + | + | − | − | + | + | nd | − |
| 2D | + | + | + | + | + | − | − | ni | +/− | ni | − |
| 3E | + | +/− | − | + | − | − | − | − | + | − | − |
| 3F | + | − | − | + | − | − | − | E | + | − | − |
| 4 | + | + | E | E | − | − | − | − | E | + | − |
| 5 | + | + | + | E | + | + | − | −/+ | − | −/+ | − |
| 6 | + | +/− | + | + | ni | − | − | ni | −/+ | + | − |
| 7 | + | ni | + | + | ni | − | − | ni | ni | ni | − |
| 8 | + | + | − | + | + | − | − | − | + | + | − |
| 9 | + | + | −/+ | +/− | − | − | − | − | − | E | − |
| 10 | + | + | + | + | + | − | − | ni | ni | ni | − |
| 11 | + | −/+ | +/− | +/− | + | − | − | ni | + | + | − |
+ indicates positive; nd, not done; −, negative; −/+, less than 50% of CD30+ cells; E, less than 10% of CD30+cells; ni, not interpretable; +/−, more than 50% of CD30+ cells.